Literature DB >> 12682814

Serotyping and genotyping of hepatitis C virus in Belgium.

L De Cock1, R Vranckx.   

Abstract

BACKGROUND: Given that both pathogenicity and the response to treatment are possibly associated with hepatitis C virus (HCV) serotype, it appeared sensible to establish the prevalence of the different HCV types in Belgium.
MATERIALS AND METHODS: The HCV serotypes were determined in 68 HCV-RNA and anti-HCV-positive samples taken from Belgian patients and compared with the results of the genotyping assay. Possible associations with age and sex were investigated.
RESULTS: Antibodies were identified in 55 (80.9%) of the 68 samples, with serotype 1 (58.8%) and serotype 3 (19.1%) showing the highest prevalence. 17 samples contained several serotypes with serotype 1 being detected in 82.4% of cases. Nine of the 11 samples undetermined by serotyping could be determined by genotyping. There was no significant difference in the distribution of HCV types with respect to gender. Compared with genotype 3 (p < 0.01) and genotypes 2 and 4 (p = 0.05), genotype 1 was detected among older patients.
CONCLUSION: Our data showed a 96.0% correlation between the serotyping and genotyping assays. Genotypes 1 and 3 are the most prevalent types among Belgian patients. The data suggest that genotype 1 spread earlier than genotypes 2, 3 and 4. This corroborates previous European studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12682814     DOI: 10.1007/s15010-002-3001-5

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  2 in total

1.  Molecular epidemiology of hepatitis C virus and its relation with persistence or clearance of infection in Hamadan, West-Iran.

Authors:  Ghasem Solgi; Masoud Sabouri Ghannad; Alireza Khalilian; Amir Majlesi; Mehrdad Hajiloo
Journal:  Iran J Microbiol       Date:  2015-04

2.  Distribution of HCV genotypes in Belgium from 2008 to 2015.

Authors:  Lobna Bouacida; Vanessa Suin; Veronik Hutse; Michaël Boudewijns; Reinoud Cartuyvels; Laurent Debaisieux; Emmanuel De Laere; Marie Hallin; Nicolas Hougardy; Katrien Lagrou; Els Oris; Elizaveta Padalko; Marijke Reynders; Gatien Roussel; Jean-Marc Senterre; Michel Stalpaert; Dominique Ursi; Carl Vael; Dolores Vaira; Jos Van Acker; Walter Verstrepen; Steven Van Gucht; Benoit Kabamba; Sophie Quoilin; Gaëtan Muyldermans
Journal:  PLoS One       Date:  2018-12-05       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.